# OnCo record nct02678572 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02678572/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02678572", "NCT02678572" ;
  schema:name "FOCUS"@en ;
  schema:alternateName "PHP-OCM-301A"@en, "PHP-OCM-301"@en, "Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma"@en ;
  schema:description "FOCUS showed that pumping high-dose melphalan through the liver's blood supply, then filtering it out before the blood returns to the body, shrank tumours in about one in three patients whose eye melanoma had spread to the liver, and it supported the treatment's US approval in 2023."@en ;
  schema:url <https://onco.cc/trials/nct02678572/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02678572>, <https://doi.org/10.1245/s10434-024-15293-x>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f83c8f7-4cc0-4219-88d5-7cfddce91198> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2016-02-01" ;
  onco:related <https://onco.cc/trials/imcgp100-202/>, <https://onco.cc/trials/nct06519266/> ;
  onco:cancers <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/percutaneous-hepatic-perfusion/> ;
  onco:drugs <https://onco.cc/drugs/hepzato/>, <https://onco.cc/drugs/melphalan/> ;
  onco:companies <https://onco.cc/companies/delcath/> ;
  onco:people <https://onco.cc/people/reinhard-dummer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zager-ann-surg-oncol/> .